Clinical trial · Interventional
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
Human Papillomavirus (HPV) Vaccination for the Treatment of Refractory Cutaneous Warts: A Randomized, Placebo-Controlled, Double-Blinded Trial
NCT05625633CI-TRIAL-00075772recruitingPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Warts | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Human Papillomavirus 9-valent Vaccine, Recombinant | Biological | — | UNRESOLVED |
| Normal Saline | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- HPV Vaccine
- description
- 0.5-mL suspension of 9-valent Gardasil vaccine administered as intramuscular injection at weeks 0, 4, and 20
- interventionNames
- Biological: Human Papillomavirus 9-valent Vaccine, Recombinant
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- 0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20
- interventionNames
- Other: Normal Saline
Primary outcomes (3)
- measure
- Assessing the efficacy/therapeutic response of HPV vaccination for the treatment of refractory cutaneous warts (response information may be found in description) at 24 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Must be able to understand and provide written informed consent 2. Age 18 or older 3. Clinical diagnosis of cutaneous warts 4. Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.) Exclusion Criteria: 1. Untreated cutaneous warts 2. Anogenital warts 3. Oral warts 4. Treatment for cutaneous warts in the past 4 weeks 5. Active acute illness 6. Immunosuppression 7. Known hypersensitivity to HPV vaccination 8. Subjects may not receive any other investigational treatment 9. Pregnancy or planned pregnancy during the study period
References
Publications (0)
Data not yet available
No reference posted for this study.